Drug Target Review
OCTOBER 4, 2023
10 Proteasome inhibitors Since the approval of Bortezomib in 2003, 11 new proteasome inhibitors have emerged with reduced side effects. More recently, researchers have begun to look at conjugating immunomodulatory agents to antibodies to directly activate an immune response against the tumour.
Drug Target Review
NOVEMBER 17, 2023
NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
FEBRUARY 28, 2024
from 2003 to 2006, covering the biotechnology and life-science tools sectors. Earlier in his career, Mr Ho was responsible for FP&A and operational analysis at CuraGen Corporation and worked as an Associate on the Healthcare Investment Banking team at Cowen, Inc. gammadelta T cells link innate and adaptive immune responses.
The Pharma Data
OCTOBER 18, 2021
The study also found mice immunized with a SARS-CoV-1 vaccine developed in 2004 generated immune responses that protected them from intranasal exposure by SARS-CoV-2. “We found that these individuals developed antibody responses that neutralized a common cold coronavirus, HCoV-OC43,” Penaloza-MacMaster said.
The Pharma Data
NOVEMBER 9, 2020
Combining ICIs with radiation therapy is emerging as a valuable strategy to “prime” an immune response and thereby increase the response rate, however the efficacy of radiation therapy is limited by toxicities related to the exposure of healthy tissues. NBTXR3 is injected one time, directly into solid tumors.
NIH Director's Blog: Drug Development
MARCH 18, 2021
These days, the Veesler lab has been hard at work to understand SARS-CoV-2 and the human immune response to the virus. He’s also a member of the international research team that identified a human antibody, called S309, from a person who’d been infected with SARS in 2003.
NIH Director's Blog: Drug Development
MAY 21, 2020
In work described in the journal Nature , an international research team started with a set of neutralizing antibodies previously identified in a blood sample from a person who’d recovered from a different coronavirus-caused disease, called severe acute respiratory syndrome (SARS), in 2003 [3]. In the U.S. medRxiv.
Expert insights. Personalized for you.
126 
Let's personalize your content